Which GLP-1 causes the most weight loss?

Tirzepatide trials typically report larger average weight losses than semaglutide in head-to-head and indirect comparisons, but side effects and individual response vary.

Is one drug safer than another?

Safety profiles overlap; differences are dose-related and patient-specific — consult your clinician for personalized risk assessment.

Ozempic vs Wegovy vs Zepbound vs Mounjaro — Honest Comparison

A practical, no-nonsense comparison of the major GLP-1/GIP medications: how they differ on weight loss, side effects, dosing, and real-world access.

Short answer: tirzepatide (Mounjaro/SURMOUNT) shows larger average weight loss in trials than semaglutide (Ozempic/Wegovy), but it has different side-effect and dosing considerations. Choice depends on goals, side-effect tolerance, cost, and access.

Which drug produces the largest average weight loss?

Direct answer: tirzepatide trial programs (SURMOUNT) reported higher average percent weight loss than semaglutide STEP trials at comparable timelines; the difference is meaningful at a population level but may not predict an individual's result.

How do side effects differ?

Direct answer: nausea, GI upset, and transient appetite changes are common across the class. Some patients report more GI intolerance on higher-dose tirzepatide; others tolerate it well. Dose titration protocol matters more than brand for early tolerability.

Which drug is easier to access or cheaper?

Direct answer: access varies. Telehealth programs may bundle certain drugs; insurance coverage often depends on indication and prior authorization. Cost calculators on this site can help compare options.

How should you pick between these drugs?

Direct answer: prioritize clinical indication (diabetes vs obesity), prior GLP-1 response, side-effect tolerance, cost/coverage, and whether maximal average weight loss is the main goal.

Quick comparison table (trial-level averages)

Semaglutide (Ozempic/Wegovy): ~12–17% avg weight loss at 68 weeks (STEP data)
Tirzepatide (Mounjaro/SURMOUNT): ~18–25% avg weight loss at similar timelines
Zepbound: (latency/market differences), consult current labeling

When should you choose one over the other?

Direct answer: choose tirzepatide if the priority is larger average weight loss and you can tolerate it and access it; choose semaglutide if you prefer the longer safety record and dosing familiarity.

What are the cost and access considerations?

Direct answer: telehealth programs, pharmacy cash, and insurance produce very different OOP costs. Use our Cost Comparison Calculator and discuss prior authorization strategies with your clinician.

What is the final takeaway?

Direct answer: the drugs differ on averages and logistics — pick based on your priorities (max loss vs tolerability vs cost) and work with your clinician to manage titration safely.

FTC Disclosure

FTC Disclosure: No affiliate links in this piece at publish time.

Medical Disclaimer

This is educational content only. Discuss options with a qualified clinician.